Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2018

View Archived Issues

Germline variants, tumor variation

Monalizumab's mysteries

Placenta organoids to give insights into pregnancy's mysteries

Advanced Accelerator Applications and Fujifilm Toyama sign license agreement for FF-10158 for cancer

Novo Nordisk initiates phase II study of once-weekly insulin 287 in type 2 diabetes

Oryzon initiates phase IIa study of iadademstat in second-line SCLC

Calygene Biotechnology patents new ML1 antagonists

University of Pennsylvania divulges anti-PF-4 antibodies

aTyr Pharma initiates phase Ib/IIa study of ATYR-1923 in patients with pulmonary sarcoidosis

University of Louisville stem cell-derived exosomes for cancer

ALLO-715 CAR T cells exhibit antitumor potency in in vitro and in vivo models of R/R MM

New PROTAC DT-2216 shows promising preclinical activity against BCL-X(L)-dependent tumors

Novel degraders of IRAK-4 demonstrate promising preclinical activity in ABC-DLBCL models

GRB10 identified as a novel therapeutic target in AML

DCB-HDG2-411 shows promising preclinical activity for Hh pathway-driven cancers

GPA-500 reduces tumor growth in models of enzalutamide-resistant prostate cancer

Exelixis and Ipsen initiate COSMIC-312 phase III study of cabozantinib plus atezolizumab in HCC

Aridis announces new milestones in AR-501 development

Faron identifies optimal subgroup of patients for Traumakine treatment in INTEREST study

First patient dosed in phase II study of MEDI-0457 plus durvalumab in HPV-associated cancers

Carnot Biosciences and HemoShear Therapeutics to develop protein-based therapeutics

PersImmune presents first-in-human data for PACTN in MDS

FLT180a gene therapy safe in first two hemophilia B patients in clinical trial

Hookipa Biotech initiates phase II study of HB-101 in kidney transplant patients

ImmuneMed initiates phase I study of hzVSF-v13

Cytokinetics begins clinical testing of CK-3773274

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...